Ophthalmological evaluation in thyroid-associated ophthalmopathy

Area of Science:

• Ophthalmology
• Endocrinology
• Autoimmune Diseases

Background:

• Thyroid-associated ophthalmopathy (TAO) is a debilitating autoimmune condition linked to Graves' disease.
• Current treatments for TAO have significant side effects and limited efficacy in restoring function and appearance.
• Effective TAO management requires precise patient evaluation, considering timing and therapeutic choices.

Purpose of the Study:

• To delineate the clinical symptoms and signs of Thyroid-associated ophthalmopathy (TAO).
• To establish the relevance of these clinical features for guiding TAO management strategies.

Main Methods:

• Review of clinical manifestations of Thyroid-associated ophthalmopathy (TAO).
• Analysis of the relationship between clinical signs and therapeutic decision-making.
• Evaluation of disease phases (active vs. inactive) and their impact on treatment selection.

Main Results:

• TAO presents an active inflammatory phase typically lasting 6-24 months, potentially extending for years.
• Disease severity, indicated by optic nerve, corneal, muscle involvement, exophthalmos, and patient-reported outcomes, dictates therapy indication.
• Inflammatory activity is crucial for selecting the appropriate therapeutic modality.

Conclusions:

• Immunosuppressive therapy is recommended during the active inflammatory phase of TAO.
• Reconstructive surgery for TAO should be deferred until the inactive phase of the disease.
• Emergency surgical intervention may be necessary for vision-threatening complications during the active TAO stage.